- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03060785
Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women
July 17, 2018 updated by: Johns Hopkins University
This is an open-label, steady-state study of Tenofovir (TFV) and Emtricitabine (FTC) pharmacokinetics (PK) in transgender women taking feminizing hormones.
Half of the participants will be transgender women on feminizing hormones, the other half will be male volunteers not taking any hormone therapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigators propose an open-label, steady-state study of TFV and FTC PK in blood and colon tissue in healthy TGW on feminizing hormones to be compared to healthy cis men, all at risk for HIV infection.
Research participants will already have received eight days of TDF/FTC dosing.
Evaluating TDF and FTC PK at steady-state is important as it reduces inter-individual variability since the rate of phosphorylation of TFV and FTC is highly variable, resulting in highly variable TFV-DP and Emtricitabine-Triphosphate (FTC-TP) PK among individuals in the first day and during rise to steady-state.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University Drug Development Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- TGW and cis men (male at birth and not a TGW)
- 18 to 65 years of age, inclusive on the date of screening
- Provides informed consent for the study
- Non-reactive HIV test results within four weeks of enrollment
- An estimated calculated creatinine clearance (eCcr) of at least 70 mL/min
- Agrees to use condoms for all sexual events during study participation.
- Taking daily oral Truvada® (Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg) for at least one week at the time of study PK sampling visit
- TGW have to be on an estradiol and have a serum total estradiol level > 100 picograms(pg)/ml
Exclusion Criteria:
- Significant colorectal symptom(s) as determined by medical history or by participant self-report
- Participant-reported symptoms and/or clinical or laboratory diagnosis of active rectal infection requiring treatment per current Centers for Disease Control (CDC) guidelines
- A positive test for Herpes Simplex Virus -2 (HSV-2) (individuals with active lesions only)
- Co-enrollment in any other HIV interventional research study (excluding behavioral only interventions) or prior enrollment in the active arm of a HIV vaccine trial.
- Positive hepatitis B surface antigen (HBsAg) test
- Interleukin therapy; medications with significant nephrotoxic potential, including but not limited to amphotericin B, aminoglycosides, cidofovir, foscarnet and systemic chemotherapy; medications that may inhibit or compete for elimination via active renal tubular secretion (including but not limited to probenecid); systemic immunomodulatory medications
- Participants with a history of having a gastrectomy, colostomy, ileostomy, or any other procedure altering the gastrointestinal tract or drug absorption
- Medications that prolong clotting time
- Any other condition or prior therapy that, in the opinion of the investigator, would preclude informed consent, make study participation unsafe, make the individual unsuitable for the study or unable to comply with the study requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TFV/FTC dosing in Transgender women
Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)for 7days in transgender women taking feminizing hormones
|
Other Names:
|
Active Comparator: TFV/FTC dosing in Cis men
Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) for 7days in cis men
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Colon tissue tenofovir diphosphate (TFV-DP)
Time Frame: One week
|
Endoscopy will be performed to obtain colorectal tissue biopsies.
15 biopsies will be collected and processed to isolate mucosal mononuclear cells (MMC).
TFV-DP will be measured and reported as femtomoles per million cells (fmole/10E6 cells).
|
One week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ex vivo colon explant HIV challenge
Time Frame: One week
|
Colorectal tissue biopsies will be collected and exposed ex vivo to HIV and kept in culture for 15 days.
Every three days a sample of fluid bathing the tissue sample will be tested for HIV p24 antigen.
Results will be reported as picograms of p24 per milliliter (pg/mL).
|
One week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 8, 2016
Primary Completion (Actual)
May 31, 2018
Study Completion (Actual)
May 31, 2018
Study Registration Dates
First Submitted
February 17, 2017
First Submitted That Met QC Criteria
February 17, 2017
First Posted (Actual)
February 23, 2017
Study Record Updates
Last Update Posted (Actual)
July 18, 2018
Last Update Submitted That Met QC Criteria
July 17, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00092121
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Prevention
-
Prof Mags BeksinskaCompletedHIV Prevention | Pregnancy PreventionSouth Africa
-
Yale UniversityCompletedHIV Prevention | STI PreventionUnited States
-
Centers for Disease Control and PreventionUniversity of Minnesota; The Fenway Institute; AIDS Action Committee of Massachusetts and other collaboratorsCompletedHIV Prevention | STD PreventionUnited States
-
International Partnership for Microbicides, Inc.CompletedHIV PreventionSouth Africa, Uganda
-
Microbicide Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompleted
-
Fenway Community HealthCompleted
-
University of California, Los AngelesUniversity of California, San Diego; California HIV/AIDS Research Program; Los... and other collaboratorsCompletedHIV PreventionUnited States
-
Microbicide Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedHIV PreventionUganda, South Africa, Zimbabwe
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompleted
-
Orion Biotechnology Polska Sp. z o.o.Scope International AGCompleted
Clinical Trials on Tenofovir Disoproxil Fumarate/Emtricitabine
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompleted
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompletedHIV InfectionsSouth Africa, Uganda, Zimbabwe
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV InfectionsUnited States, Puerto Rico
-
University of WashingtonBill and Melinda Gates FoundationCompletedHIV Infections | HIV-1 InfectionsKenya, Uganda
-
CONRADEastern Virginia Medical School; University of North Carolina; Agility Clinical...Completed
-
University of KwaZuluMedical Research Council, South Africa; Centre for the AIDS Programme of Research...Completed
-
University of ManitobaWorld Health Organization; DMSC; Ashodaya SamithiCompleted
-
University of HawaiiGilead SciencesUnknown
-
Merck Sharp & Dohme LLCActive, not recruitingProphylaxis | Human Immunodeficiency Virus Type 1 | HIV-IUnited States, South Africa, Uganda
-
University of California, San DiegoGilead Sciences; University at BuffaloCompleted